158205-05-1

Basic information

• Product Name: Methanesulfonamide,N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]-
• Synonyms: L 745337;N-[6-[(2,4-Difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]methanesulfonamide;Thioflosulide
• CAS NO: 158205-05-1
• Molecular Formula: C16H13 F2 N O3 S2
• Molecular Weight: 369.413
• Mol File: 158205-05-1.mol

Chemical Properties

• Boiling Point: 495.8±55.0 °C(Predicted)
• Density: 1.52±0.1 g/cm3(Predicted)
• CAS DataBase Reference: Methanesulfonamide,N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonamide,N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]-(158205-05-1)
• EPA Substance Registry System: Methanesulfonamide,N-[6-[(2,4-difluorophenyl)thio]-2,3-dihydro-1-oxo-1H-inden-5-yl]-(158205-05-1)

Safety Data

• Hazardous Substances Data: 158205-05-1(Hazardous Substances Data)

Upstream product

• 170456-58-3 5--6-(2,4-difluorophenylthio)-1-indanone 
• 24425-40-9 indan-5-amine 
• 157701-33-2 5-acetylamino-6-bromoindane 
• 59856-06-3 5-acetamidoindane 
• 367-27-1 2,4-difluorophenol 
• 1996-44-7 2,4-difluorothiophenol 
• 124-63-0 methanesulfonyl chloride 
• 158205-23-3 5-amino-6-<(2,4-difluorophenyl)thio>-1-indanone 
• 170456-60-7 S-(2,4-difluorophenyl)dimethylthiocarbamate 
• 170456-59-4 O-(2,4-difluorophenyl)dimethylthiocarbamate 
• 158205-22-2 6-<(2,4-difluorophenyl)thio>-5-nitro-1-indanone ethylene ketal 
• 158205-21-1 5-nitro-6-bromo-1-indanone ethylene ketal 
• 158205-18-6 5-Acetylamino-6-bromo-1-indanone 
• 158205-20-0 5-nitro-6-bromo-1-indanone 

Relevant articles and documents

Method for the treatment and prevention of cachexia

Cachexia, including anorexia and other forms of weight loss, is a frequent complication of acute and chronic infections, and result from induction of cytokines, prostaglandins, and other inflammatory mediators that are critical for pathogen elimination. The present invention includes methods for the treatment or prevention of cachexic conditions while maintaining the production of factors essential for infection control through the administration of an effective amount of a cyclooxygenase-2 selective inhibiting compound.

Antiangiogenic combination therapy for the treatment of cancer

The present invention provides combinations of a DNA topoisomerase I inhibiting agent and a selective COX-2 inhibiting agent for preventing, treating, and/or reducing the risk of developing a neoplasia disorder in a mammal.

5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2

The Compound of Formula I and pharmaceutically acceptable salts thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.

Cyclooxygenase-2 inhibitors. Synthesis and pharmacological activities of 5-methanesulfonamido-1-indanone derivatives

The recent discovery of an alternative form cyclooxygenase (cyclooxygenase-2, COX-2), which has been proposed to play a significant role in inflammatory conditions, may provide an opportunity to develop anti- inflammatory drugs with fewer side effects tha

Synthesis of 5-methanesulfonamido-6-(2,4-difluorophenylthio)-1-indanone

The ethylene ketal of 5-nitro-6-bromo-1-indanone 6 was prepared via oxidation of N-(6-Bromo-5-indanyl)-acetamide 1. A subsequent mild displacement and elaboration to 6-thiosubstituted-5-amino indanone derivative 10 is also described.